121 related articles for article (PubMed ID: 12772509)
1. Enhancing immunogenicity by CpG DNA.
Jiang W; Pisetsky DS
Curr Opin Mol Ther; 2003 Apr; 5(2):180-5. PubMed ID: 12772509
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the development of immunostimulatory oligonucleotides.
Uhlmann E; Vollmer J
Curr Opin Drug Discov Devel; 2003 Mar; 6(2):204-17. PubMed ID: 12669456
[TBL] [Abstract][Full Text] [Related]
3. Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides.
Wilson HL; Dar A; Napper SK; Marianela Lopez A; Babiuk LA; Mutwiri GK
Int Rev Immunol; 2006; 25(3-4):183-213. PubMed ID: 16818371
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in immunostimulatory CpG oligonucleotides.
Rothenfusser S; Tuma E; Wagner M; Endres S; Hartmann G
Curr Opin Mol Ther; 2003 Apr; 5(2):98-106. PubMed ID: 12772497
[TBL] [Abstract][Full Text] [Related]
5. Non-CpG-containing antisense 2'-methoxyethyl oligonucleotides activate a proinflammatory response independent of Toll-like receptor 9 or myeloid differentiation factor 88.
Senn JJ; Burel S; Henry SP
J Pharmacol Exp Ther; 2005 Sep; 314(3):972-9. PubMed ID: 15919763
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant activity of CpG oligodeoxynucleotides.
Klinman DM
Int Rev Immunol; 2006; 25(3-4):135-54. PubMed ID: 16818369
[TBL] [Abstract][Full Text] [Related]
7. TLR9-/- and TLR9+/+ mice display similar immune responses to a DNA vaccine.
Babiuk S; Mookherjee N; Pontarollo R; Griebel P; van Drunen Littel-van den Hurk S; Hecker R; Babiuk L
Immunology; 2004 Sep; 113(1):114-20. PubMed ID: 15312142
[TBL] [Abstract][Full Text] [Related]
8. Toll-like receptors involved in the response to microbial pathogens: development of agonists for toll-like receptor 9.
Schetter C; Vollmer J
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):204-10. PubMed ID: 15603254
[TBL] [Abstract][Full Text] [Related]
9. Towards optimal design of second-generation immunomodulatory oligonucleotides.
Kandimalla ER; Yu D; Agrawal S
Curr Opin Mol Ther; 2002 Apr; 4(2):122-9. PubMed ID: 12044033
[TBL] [Abstract][Full Text] [Related]
10. Technology evaluation: CpG-7909, Coley.
Paul S
Curr Opin Mol Ther; 2003 Oct; 5(5):553-9. PubMed ID: 14601526
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant properties of CpG oligonucleotides in primates.
Verthelyi D
Methods Mol Med; 2006; 127():139-58. PubMed ID: 16988453
[TBL] [Abstract][Full Text] [Related]
12. CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy.
Chaung HC
Int Immunopharmacol; 2006 Oct; 6(10):1586-96. PubMed ID: 16919831
[TBL] [Abstract][Full Text] [Related]
13. TLR9 signals after translocating from the ER to CpG DNA in the lysosome.
Latz E; Schoenemeyer A; Visintin A; Fitzgerald KA; Monks BG; Knetter CF; Lien E; Nilsen NJ; Espevik T; Golenbock DT
Nat Immunol; 2004 Feb; 5(2):190-8. PubMed ID: 14716310
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleotides.
Ishii KJ; Gursel I; Gursel M; Klinman DM
Curr Opin Mol Ther; 2004 Apr; 6(2):166-74. PubMed ID: 15195929
[TBL] [Abstract][Full Text] [Related]
15. Structural requirements for uptake and recognition of CpG oligonucleotides.
Heeg K; Dalpke A; Peter M; Zimmermann S
Int J Med Microbiol; 2008 Jan; 298(1-2):33-8. PubMed ID: 17706458
[TBL] [Abstract][Full Text] [Related]
16. Chloroquine protects mice from challenge with CpG ODN and LPS by decreasing proinflammatory cytokine release.
Hong Z; Jiang Z; Liangxi W; Guofu D; Ping L; Yongling L; Wendong P; Minghai W
Int Immunopharmacol; 2004 Feb; 4(2):223-34. PubMed ID: 14996414
[TBL] [Abstract][Full Text] [Related]
17. CpG motifs to modulate innate and adaptive immune responses.
Vollmer J
Int Rev Immunol; 2006; 25(3-4):125-34. PubMed ID: 16818368
[TBL] [Abstract][Full Text] [Related]
18. TLR9 pathway is involved in adjuvant effects of plasmid DNA-based vaccines.
Tudor D; Dubuquoy C; Gaboriau V; Lefèvre F; Charley B; Riffault S
Vaccine; 2005 Jan; 23(10):1258-64. PubMed ID: 15652668
[TBL] [Abstract][Full Text] [Related]
19. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.
Vollmer J; Weeratna RD; Jurk M; Davis HL; Schetter C; Wüllner M; Wader T; Liu M; Kritzler A; Krieg AM
J Leukoc Biol; 2004 Sep; 76(3):585-93. PubMed ID: 15218053
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists.
Kandimalla ER; Bhagat L; Li Y; Yu D; Wang D; Cong YP; Song SS; Tang JX; Sullivan T; Agrawal S
Proc Natl Acad Sci U S A; 2005 May; 102(19):6925-30. PubMed ID: 15860583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
